Vertex Pharmaceuticals
VRTX
582 hedge funds and large institutions have $30.4B invested in Vertex Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 219 increasing their positions, 183 reducing their positions, and 37 closing their positions.
173% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 37
146% more call options, than puts
Call options by funds: $416M | Put options by funds: $169M
20% more repeat investments, than reductions
Existing positions increased: 219 | Existing positions reduced: 183
18% more capital invested
Capital invested by funds: $25.8B → $30.4B (+$4.61B)
11% more funds holding
Funds holding: 522 → 582 (+60)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
0.2% less ownership
Funds ownership: 95% → 94.8% (-0.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$437M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$193M |
| 3 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
+$134M |
| 4 |
Morgan Stanley
New York
|
+$128M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$72.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$299M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$228M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$221M |
| 4 |
JP Morgan Chase
New York
|
-$118M |
| 5 |
Goldman Sachs
New York
|
-$105M |
VRTX Hedge Fund Activity: Q2 2017 in Review
582 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2017, worth a combined $30.4B — up 18% from $25.8B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new VRTX positions and 37 closed out — a net gain of 64 holders — while 219 added to existing stakes and 183 trimmed.
The largest buyer was Jennison Associates, adding an estimated $437M. The largest seller was Capital World Investors, cutting an estimated $299M.
- 582 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2017, up from 522 in Q1 2017.
- Funds reported $30.4B of Vertex Pharmaceuticals stock for Q2 2017, up 18% quarter-over-quarter.
- 101 funds opened new Vertex Pharmaceuticals positions in Q2 2017 and 37 closed out, a net change of +64 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2017 was Jennison Associates, an estimated $437M added.
- The largest Vertex Pharmaceuticals seller in Q2 2017 was Capital World Investors, an estimated $299M sold.
Based on aggregated 13F filings for Q2 2017.